Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its financial results for the third quarter of 2024, alongside significant corporate updates. The company marked a pivotal milestone with …
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to …
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the 2024 Cantor Global Healthcare Conference, with a management team set to engage in a fireside chat on September …
Aclaris Therapeutics Engages in 2024 Cantor Global Healthcare Conference Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its financial results for the second quarter of 2024 and provided a corporate update. The company reported net revenue of $2.8 …
Aclaris Therapeutics Reports Q2 2024 Financial Results and Updates Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, Interim President and CEO, will join a fireside chat at the Goldman Sachs 45th Annual Global Healthcare …
Aclaris Therapeutics to Participate in Goldman Sachs Healthcare Conference Read More WAYNE, PA — Aclaris Therapeutics (NASDAQ: ACRS), a noted bio-pharmaceutical firm, has made public its financial results for the first quarter of 2024. The announcement was made amidst an outline …
Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital-Efficient Immuno-Inflammatory Therapies Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a key player in the pharmaceutical industry, is set to release its financial outcomes for the first quarter of 2024 on May …
Aclaris Therapeutics to Announce Q1 Financial Results and Host Conference Call Read More WAYNE, PA — Hailed as a leader in kinase discovery and development, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) began 2024 in a robust financial position, charting an ambitious course for the …
Aclaris Therapeutics: A Year of Financial Resilience and Steady Advancements Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a biopharmaceutical company specializing in dermatological treatments, has announced significant changes to its leadership and an impending strategic review of its business …
Aclaris Therapeutics Announces Leadership Shake-up and Strategic Review, Investors Watch Closely Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …
Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More